Free shipping on all orders over $ 500

SNS-032

Cat. No. M2065

All AbMole products are for research use only, cannot be used for human consumption.

SNS-032 Structure
Synonym:

BMS-387032

Size Price Availability Quantity
1mg USD 25 In stock
5mg USD 50 In stock
10mg USD 70 In stock
50mg USD 150 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SNS-032 (formerly BMS-387032) is a small-molecule cyclin-dependent kinases (CDK) inhibitor. SNS-032 arrests the cell cycle at G2/M; inhibits transcription, proliferation and colony formation, and induces apoptosis in RPMI-8226 multiple myeloma cells. SNS-032 (BMS-387032) prevents tumor cell-induced VEGF secretion and in vitro angiogenesis. SNS-032-induced a dose-dependent increase in annexin V staining and caspase-3 activation. At the molecular level, SNS-032 induced a marked dephosphorylation of serine 2 and 5 of RNA polymerase (RNA Pol) II and inhibited the expression of CDK2 and CDK9 and dephosphorylated CDK7. SNS-032 effectively killed chronic lymphocytic leukemia cells in vitro. At the dose levels tested, the oral bioavailability of SNS-032 ranged from 4-33%. SNS-032 is currently in phase I clinical trials for the treatment of B-cell malignancies and advanced solid tumors.

Chemical Information
Molecular Weight 380.53
Formula C17H24N4O2S2
CAS Number 345627-80-7
Solubility (25°C) DMSO 68 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Walsby E, et al. Leukemia. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.

[2] Chen R, et al. Cancer Res. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.

[3] Chen R, et al. Blood. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

Related CDK Products
AT7519

AT7519 is a novel small molecule multi-cyclin-dependent (CDK) kinase inhibitor.

Flavopiridol

Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively.

R547

R547 is a potent and selective ATP-competitive CDK inhibitor, with Ki values of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively.

JNJ-7706621

JNJ-7706621 is a dual cell cycle inhibitor with activity against cyclin-dependent kinases (CDK1, 2, 3, 6) with an IC50 of 3-175 nM and Aurora kinases (A and B) with an IC50 of 11-15 nM respectively.

PD 0332991 HCL

PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc.

  Catalog
Abmole Inhibitor Catalog




Keywords: SNS-032, BMS-387032 supplier, CDK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.